Start with lovers who work for competing generic drug manufacturers. OK, that’s enough. Teva Pharmaceuticals alleges that one of its former top executives told her boyfriend, the CEO of rival Apotex, about what medicines Teva was manufacturing and which were close to being approved by the FDA, the Philadelphia Inquirer reports.
“Barinder Sandhu was Teva’s senior director of regulatory affairs for U.S. generics between 2014 and 2016 when, the lawsuit says, she used USB flash drives to download confidential files on her work-issued laptop — and synced a folder titled “My Drive” with about 900 documents to a cloud-based account — and sent them to Jeremy Desai at his email account at Toronto-based Apotex, Canada’s largest manufacturer of generic pharmaceuticals,” the newspaper reports.
A lawsuit filed in U.S. District Court on July 7 says that what went on between Sandhu and Desai violates the Defend Trade Secrets and Computer Fraud and Abuse Acts. The named defendants are Sandu (who was fired in October), Desai, and Apotex. An Apotex spokesperson said the company wholly denies that it acted improperly.
“According to court documents, the communications came to light after a former Apotex employee reported last summer that Desai and Apotex had openly discussed information about an unnamed drug, Product X, that Teva was developing and that competed with an Apotex product,” the newspaper reports.
Apotex has more than 10,000 employees and annual sales of approximately $2 billion. Teva has about 57,000 employees and sales of about $22 billion.
Source: Philadelphia Inquirer (link is external)
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweißen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.